文献速递泌尿男性生殖肿瘤

局限期前列腺癌根治性放疗中雄激素剥夺治疗的使用与疗程:个体患者数据荟萃分析

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
PubMed 文献 · Lancet Oncol · 2022-01-17

该个体患者数据荟萃分析纳入12项多中心随机试验共10853例接受根治性放疗的局限期前列腺癌患者,中位随访11.4年。结果显示放疗联合ADT显著改善无转移生存(HR 0.83,95%CI 0.77-0.89,p<0.0001),辅助期ADT延长亦显著改善(HR 0.84,95%CI 0.78-0.91,p<0.0001),而新辅助期ADT延长无显著获益(HR 0.95,95%CI 0.83-1.09,p=0.50)。

要点

  • 放疗联合ADT较单纯放疗显著改善无转移生存(HR 0.83,95%CI 0.77-0.89)。
  • 辅助期ADT延长显著改善无转移生存(HR 0.84,95%CI 0.78-0.91)。
  • 新辅助期ADT延长未显著改善无转移生存(HR 0.95,95%CI 0.83-1.09)。

核心结论

  • 放疗联合ADT及延长放疗后ADT疗程与无转移生存改善相关,且不受风险组、年龄和放疗剂量影响。
  • 作者建议与患者进行共同决策,获益幅度可能有所不同。

研究设计与样本

  • 系统检索MEDLINE、Embase、试验注册库、Web of Science、Scopus和会议论文集,纳入1962年1月1日至2020年12月30日发表英文结果的试验。
  • 纳入评估局限期前列腺癌根治性放疗中ADT使用或延长(或两者)的多中心随机试验,要求报告或收集远处转移和生存数据,且ADT为方案规定的有限疗程。
  • 通过MARCAP联盟获取随机试验的个体患者数据,共纳入12项试验、10853例患者,中位随访11.4年(IQR 9.0-15.0)。

主要发现

  • 放疗联合ADT较单纯放疗显著改善无转移生存(HR 0.83,95%CI 0.77-0.89,p<0.0001)。
  • 辅助期ADT延长(从4-6个月延长至18-36个月)显著改善无转移生存(HR 0.84,95%CI 0.78-0.91,p<0.0001)。
  • 新辅助期ADT延长(从3-4个月延长至6-9个月)未显著改善无转移生存(HR 0.95,95%CI 0.83-1.09,p=0.50)。
  • 按放疗剂量、患者年龄和NCCN风险组预设亚组分析,治疗效果相似。

关键数值与推荐

  • ADT使用:放疗联合ADT对比单纯放疗的无转移生存HR 0.83(95%CI 0.77-0.89,p<0.0001)。
  • 新辅助期ADT延长:从3-4个月延长至6-9个月的无转移生存HR 0.95(95%CI 0.83-1.09,p=0.50)。
  • 辅助期ADT延长:从4-6个月延长至18-36个月的无转移生存HR 0.84(95%CI 0.78-0.91,p<0.0001)。

临床怎么用

  • 作者认为,对于局限期前列腺癌接受放疗的患者,加用ADT并延长放疗后ADT疗程与无转移生存改善相关,且不受风险组、年龄和放疗剂量的影响。
  • 作者建议与患者进行共同决策,因为获益幅度可能有所不同。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer. This individual patient data meta-analysis of relevant randomised trials aimed to quantify the benefit of these interventions in aggregate and in clinically relevant subgroups. METHODS: For this meta-analysis, we performed a systematic literature search in MEDLINE, Embase, trial registries, the Web of Science, Scopus, and conference proceedings to identify trials with results published in English between Jan 1, 1962, and Dec 30, 2020. Multicentre randomised trials were eligible if they evaluated the use or prolongation of ADT (or both) in men with localised prostate cancer receiving definitive radiotherapy, reported or collected distant metastasis and survival data, and used ADT for a protocol-defined finite duration. The Meta-Analysis of Randomized trials in Cancer of the Prostate (MARCAP) Consortium was accessed to obtain individual patient data from randomised trials. The primary outcome was metastasis-free survival. Hazard ratios (HRs) were obtained through stratified Cox models for ADT use (radiotherapy alone vs radiotherapy plus ADT), neoadjuvant ADT extension (ie, extension of total ADT duration in the neoadjuvant setting from 3-4 months to 6-9 months), and adjuvant ADT prolongation (ie, prolongation of total ADT duration in the adjuvant setting from 4-6 months to 18-36 months). Formal interaction tests between interventions and metastasis-free survival were done for prespecified subgroups defined by age, National Comprehensive Cancer Network (NCCN) risk group, and radiotherapy dose. This meta-analysis is registered with PROSPERO, CRD42021236855. FINDINGS: Our search returned 12 eligible trials that provided individual patient data (10 853 patients) with a median follow-up of 11·4 years (IQR 9·0-15·0). The addition of ADT to radiotherapy significantly improved metastasis-free survival (HR 0·83 [95% CI 0·77-0·89], p<0·0001), as did adjuvant ADT prolongation (0·84 [0·78-0·91], p<0·0001), but neoadjuvant ADT extension did not (0·95 [0·83-1·09], p=0·50). Treatment effects were similar irrespective of radiotherapy dose, patient age, or NCCN risk group. INTERPRETATION: Our findings provide the strongest level of evidence so far to the magnitude of the benefit of ADT treatment intensification with radiotherapy for men with localised prostate cancer. Adding ADT and prolonging the portion of ADT that follows radiotherapy is associated with improved metastasis-free survival in men, regardless of risk group, age, and radiotherapy dose delivered; however, the magnitude of the benefit could vary and shared decision making with patients is recommended. FUNDING: University Hospitals Seidman Cancer Center, Prostate Cancer Foundation, and the American Society for Radiation Oncology.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kishan AU, Sun Y, Hartman H, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022. PMID: 35051385. doi:10.1016/S1470-2045(21)00705-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。